Trial Profile
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Belatacept (Primary)
- Indications Allotransplant rejection
- Focus Therapeutic Use
- 24 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Jun 2028.
- 24 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2027.
- 18 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.